KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum, Sara De Dosso, Dieter Koeberle, Sabina Schacher, Roman Inauen, Michael Stahl, Thierry Delaunoit, Thomas Ettrich, György Bodoky, Pierre Michel, Thibaud Koessler, Karin Rothgiesser, Sandra Calmonte, Markus Joerger

Clin Cancer Res 31(15) 3142-3149

PMID40067142
PMCIDPMC7617601
DOI10.1158/1078-0432.CCR-24-4048
发表日期2025-03-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated colon cancer. PATIENTS AND METHODS: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events. RESULTS: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27-1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%-92.0%) in the aspirin and 72.9% (90% CI, 55.7%-84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21-1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events. CONCLUSIONS: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3. Disease-free survival. Kaplan-Meier curve of disease-free survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue). Abbreviation: HR: hazard ratio

Disease-free_survival

Disease-free survival

Figure 3 · Panel Disease-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Disease-free_survival 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 4

Figure 4. Time to recurrence. Kaplan-Meier curve of time to recurrence (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue). Abbreviation: HR: hazard ratio

Time_to_recurrence

Time to recurrence

Figure 4 · Panel Time_to_recurrence

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Time_to_recurrence 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT diagram. Enrollment and distribution of patients in the study.
非 KM Figure
Figure 2Figure 2. Screened and accrued patients. Plot representing the number of screened (in red) and accrued (in blue) patients over time (between April 2016 and November 2020). Of 1’040 patients screened, 112 with PIK3CA -mutant colon cancer were included into the study.
非 KM Figure